MCL Literature Feed

This review details the evolution of BTK inhibitors, highlighting improved toxicity with newer agents and the emergence of non-covalent BTKis and novel resistance mutations, impacting MCL treatment sequencing.

This case report describes mantle cell lymphoma presenting as multiple colonic polyposis causing obstruction, highlighting a rare gastrointestinal manifestation requiring specific immunohistochemical diagnosis for confirmation.

This commentary discusses the zandelisib (PI3Ki) plus zanubrutinib (BTKi) combination, suggesting a potential role for newer, potentially less toxic PI3K inhibitors in relapsed/refractory MCL.

An editor's note highlights a preclinical study where a combined epigenetic therapy shows superior efficacy against MCL cells, suggesting a novel therapeutic strategy for clinical development.

This review positions allogeneic transplant as a key curative option for high-risk (e.g., TP53-mutated) and relapsed/refractory MCL, despite its changing role with the advent of novel therapies.

This review provides a framework for integrating bispecific antibodies into MCL treatment, addressing the critical clinical question of how to sequence them with other novel immunotherapies like CAR-T.

MYC overexpression is a critical biomarker defining high-risk mantle cell lymphoma, helping to stratify patients with poor prognosis and potentially guiding novel therapeutic approaches for this aggressive disease.

This article summarizes Israeli national guidelines for administering CAR-T therapy in relapsed/refractory MCL, detailing patient management, toxicity monitoring for CRS and ICANS, and long-term follow-up principles.

This narrative review of Malaysian B-cell lymphoma research identifies only three mantle cell lymphoma papers, highlighting a significant data gap and the need for more regional epidemiological studies.

This review, while focused on CLL, details the metabolic and toxicity profiles of covalent and non-covalent BTKis, informing MCL management strategies for adverse events and emerging resistance.

This review summarizes fundamental MCL characteristics, including the t(11;14) translocation and key high-risk features (high Ki67, blastoid variant, TP53 mutation) essential for patient risk stratification.

This review details BTK inhibitor resistance mechanisms, particularly C481S mutations, and highlights non-covalent BTKi (pirtobrutinib) and PROTACs as key strategies to overcome relapse in MCL.

This case report describes an extremely rare pancreatic collision tumor of MCL and adenocarcinoma, hypothesizing a potential role for cyclin D1 in promoting the second malignancy.

This workshop report summarizes recent advances in MCL biology and treatment, including BTKi and CAR-T, and outlines key research priorities to overcome resistance and clinical heterogeneity for future progress.

This 2024 review of 80 FDA-approved kinase inhibitors highlights pirtobrutinib's recent approval for relapsed/refractory MCL, contextualizing its properties within the broader landscape of targeted therapies.

This review summarizes the rare presentation of mantle cell lymphoma in the lacrimal sac, highlighting the unique diagnostic and multidisciplinary therapeutic challenges posed by this specific anatomical site.

This pathology workshop report clarifies the differential diagnosis of aggressive B-cell lymphomas, including pleomorphic MCL, by applying updated WHO-HAEM5 and ICC 2022 classifications for improved diagnostic accuracy.

This review analyzes the regulatory challenges and decision-making complexities for ibrutinib in MCL, stemming from inconsistent results across different pivotal clinical trials.

This paper proposes using the estimand framework to standardize definitions of Duration of Response (DOR) and Time to Response (TTR), using an MCL case study to improve trial endpoint clarity.

This review summarizes the evolution of MCL treatment, focusing on BTK inhibitor efficacy, toxicity, and their role in enabling personalized therapeutic strategies based on patient and disease factors.

Pirtobrutinib, the first approved non-covalent BTKi, offers a crucial new therapy for relapsed/refractory MCL by overcoming resistance mechanisms, including C481 mutations, from prior covalent BTK inhibitors.

This commentary highlights the new British Society for Haematology guidelines, offering updated, comprehensive recommendations for MCL diagnosis and management, including guidance for difficult-to-treat clinical scenarios.

This review synthesizes MCL's genomic heterogeneity with the evolving therapeutic landscape, focusing on novel agents like BTKi and CAR-T and strategies for overcoming resistance in relapsed/refractory disease.

Pirtobrutinib, a non-covalent BTKi, shows a 52% overall response rate in relapsed/refractory MCL, including in patients previously treated with covalent BTKi, offering a new therapeutic option.

An MCL patient with B-cell depletion had persistent COVID-19 for over 112 days, diagnosed via lower respiratory sampling, highlighting a unique vulnerability and successful treatment with convalescent plasma.

This paper outlines strategies for improved collaboration between community oncologists and authorized centers to overcome logistical and educational barriers, ensuring timely referral and access to CAR-T therapy for MCL.

This review explores targeting tumor-associated macrophages within the MCL microenvironment as a novel immunotherapeutic strategy to enhance anti-tumor activity and potentially overcome drug resistance.

This review identifies the lncRNA LINK-A as an upregulated oncogene in MCL, presenting it as a potential biomarker and therapeutic target involved in oncogenic pathways and therapy resistance.

This systematic review of real-world data supports positioning covalent BTKis as second-line therapy for relapsed/refractory MCL, followed by CAR-T cells for patients relapsing after BTKi treatment.

This review details the pathophysiology and management of CAR-T toxicities like CRS and ICANS, providing essential guidance for clinicians treating relapsed/refractory MCL patients with this therapy.